These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36318340)

  • 1. Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points.
    Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
    Support Care Cancer; 2022 Dec; 30(12):9693-9695. PubMed ID: 36318340
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.
    Fusco V; Rossi M; Fasciolo A; Gambino A; Palmeri S
    Support Care Cancer; 2022 Dec; 30(12):9707-9709. PubMed ID: 35882670
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points.
    Rossi M; Gambino A; Cabras M; Alessio M; Fusco V
    Support Care Cancer; 2021 Aug; 29(8):4185-4186. PubMed ID: 33634351
    [No Abstract]   [Full Text] [Related]  

  • 5. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 6. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab related osteonecrosis of the jaw.
    Patel V; Carey B
    Br J Oral Maxillofac Surg; 2023 Dec; 61(10):704-706. PubMed ID: 37957097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
    Ruggiero SL; Fantasia J; Carlson E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
    [No Abstract]   [Full Text] [Related]  

  • 9. Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer.
    Piccioli A
    Eur J Orthop Surg Traumatol; 2015 Jan; 25(1):29-37. PubMed ID: 24037511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Ferneini EM
    J Oral Maxillofac Surg; 2021 Aug; 79(8):1801-1802. PubMed ID: 34334170
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
    Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
    Support Care Cancer; 2022 May; 30(5):4505-4514. PubMed ID: 35113225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
    Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
    Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
    Lund T; Gregersen H; Vangsted A; Marker P; Abildgaard N
    Ugeskr Laeger; 2009 Jan; 171(1-2):50-2. PubMed ID: 19128568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
    Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
    Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
    Landesberg R; Wilson T; Grbic JT
    Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
    Van Poznak C
    Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies.
    Bantis A; Zissimopoulos A; Sountoulides P; Kalaitzis C; Giannakopoulos S; Deftereos S; Tsakaldimis G; Thomaidis V; Touloupidis S
    Tumori; 2011; 97(4):479-83. PubMed ID: 21989437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonate-induced osteonecrosis of the jaw in a patient with metastatic breast cancer].
    Amrani Raissouni T; Moya Espinosa P; Ramos Moreno E; Martínez Del Valle Torres MD; Sanz Viedma S; Ortega Lozano SJ
    Rev Esp Med Nucl; 2011; 30(5):322-3. PubMed ID: 21440957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.